Patents Assigned to NEUTROLIS, INC.
  • Engineering of DNASE enzymes for manufacturing and therapy
    Patent number: 11840712
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: December 12, 2023
    Assignee: Neutrolis, Inc.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • Engineering of DNASE enzymes for manufacturing and therapy
    Patent number: 11578314
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (DTL2), DNASE1-LIKE 3 Isoform 1 (DTL3), DNASE1-LIKE 3 Isoform 2 (DTL3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: February 14, 2023
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • Methods for treating or preventing tissue adhesions
    Patent number: 11464833
    Abstract: The present invention relates to the treatment of tissue adhesions, e.g. tissue adhesions that occur after surgical interventions. More specifically, the invention refers to an enzyme having DNAse activity for use in a method of treating or preventing tissue adhesions. The invention also relates to a pharmaceutical composition that comprises an enzyme having DNAse activity for use in a method of treating or preventing tissue adhesions.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: October 11, 2022
    Assignee: NEUTROLIS, INC.
    Inventors: Michael Boettcher, Tobias Fuchs
  • Engineered human extracellular DNASE enzymes
    Patent number: 11352613
    Abstract: The present disclosure provides a library of engineered DNASE proteins (including DNASE1, DNASE1-LIKE 1, DNASE1-LIKE 2, DNASE1-LIKE 3, DNASE2A, DNASE2B) that allows to select drug candidates for developing therapeutics for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the selected DNase variant has improved properties, including properties amenable to clinical development, including manufacturing, toxicology, pharmacokinetic, and/or use in therapy.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: June 7, 2022
    Assignee: Neutrolis, Inc.
    Inventor: Tobias A. Fuchs
  • Methods of using DNASE1-like 3 in therapy
    Patent number: 11058724
    Abstract: The present disclosure provides D1L3 enzymes having complete or partial C-terminal deletions of the basic domain (BD), which have substantially enhanced chromatin-degrading activity. In various aspects, the invention provides chromatinase enzyme therapy, which is optionally provided by delivering polynucleotides encoding chromatinases such as D1L3, or by delivering host cells expressing and secreting the same.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: July 13, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • DNase therapy for intravascular accumulation of extracellular DNA
    Patent number: 11046943
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: June 29, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • DNase therapy for intravascular accumulation of extracellular DNA
    Patent number: 11046942
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 29, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • Manufacturing and engineering of DNASE enzymes for therapy
    Patent number: 10988746
    Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: April 27, 2021
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Abdul Hakkim R.
  • Engineered DNase enzymes and use in therapy
    Patent number: 10801019
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: October 13, 2020
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • Engineered DNase enzymes and use in therapy
    Patent number: 10696956
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: June 30, 2020
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert